Nanobody-mediated neutralization of candidalysin prevents epithelial damage and inflammatory responses that drive vulvovaginal candidiasis pathogenesis
mBio · 13.03.2024 · 15 (3)
DOI: 10.1128/mbio.03409-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 13.03.2024. Verfasst von Marisa Valentine und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Ge…. Hauptthemen laut MEDLINE: Candidiasis, Vulvovaginal, Single-Domain Antibodies, Candidiasis, Fungal Proteins. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, Wellcome Trust, FunHoMic.
Abstract (Originalsprache)
Candida albicans can cause mucosal infections in humans. This includes oropharyngeal candidiasis, which is commonly observed in human immunodeficiency virus infected patients, and vulvovaginal candidiasis (VVC), which is the most frequent manifestation of candidiasis. Epithelial cell invasion by C. albicans hyphae is accompanied by the secretion of candidalysin, a peptide toxin that causes epithelial cell cytotoxicity. During vaginal infections, candidalysin-driven tissue damage triggers epithelial signaling pathways, leading to hyperinflammatory responses and immunopathology, a hallmark of VVC. Therefore, we proposed blocking candidalysin activity using nanobodies to reduce epithelial damage and inflammation as a therapeutic strategy for VVC. Anti-candidalysin nanobodies were confirmed to localize around epithelial-invading C. albicans hyphae, even within the invasion pocket where candidalysin is secreted. The nanobodies reduced candidalysin-induced damage to epithelial cells and downstream proinflammatory responses. Accordingly, the nanobodies also decreased neutrophil activation and recruitment. In silico mathematical modeling enabled the quantification of epithelial damage caused by candidalysin under various nanobody dosing strategies. Thus, nanobody-mediated neutralization of candidalysin offers a novel therapeutic approach to block immunopathogenic events during VVC and alleviate symptoms. IMPORTANCE Worldwide, vaginal infections caused by Candida albicans (VVC) annually affect millions of women, with symptoms significantly impacting quality of life. Current treatments are based on anti-fungals and probiotics that target the fungus. However, in some cases, infections are recurrent, called recurrent VVC, which often fails to respond to treatment. Vaginal mucosal tissue damage caused by the C. albicans peptide toxin candidalysin is a key driver in the induction of hyperinflammatory responses that fail to clear the infection and contribute to immunopathology and disease severity. In this pre-clinical evaluation, we show that nanobody-mediated candidalysin neutralization reduces tissue damage and thereby limits inflammation. Implementation of candidalysin-neutralizing nanobodies may prove an attractive strategy to alleviate symptoms in complicated VVC cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
- Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
- Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany.
- Junior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
- Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, England, United Kingdom.
- Institute of Applied Optics and Biophysics, Friedrich Schiller University, Jena, Germany.
ORCID-Profile: Marisa Valentine, Paul Rudolph, Marc T Figge, Mark S Gresnigt, Bernhard Hube
Förderung
- NIDCR NIH HHS
- Wellcome Trust
- FunHoMic
- Deutsche Forschungsgemeinschaft
- Freistaat Thüringen
- HHS | National Institutes of Health
- German Federal Ministry of Education
Zitieren
APA
Valentine, M., Rudolph, P., Dietschmann, A., Tsavou, A., Mogavero, S., Lee, S., Priest, E. L., Zhurgenbayeva, G., Jablonowski, N., Timme, S., Eggeling, C., Allert, S., Dolk, E., Naglik, J. R., Figge, M. T., Gresnigt, M. S., & Hube, B. (2024). Nanobody-mediated neutralization of candidalysin prevents epithelial damage and inflammatory responses that drive vulvovaginal candidiasis pathogenesis. mBio, 15(3). https://doi.org/10.1128/mbio.03409-23
Vancouver
Valentine M, Rudolph P, Dietschmann A, Tsavou A, Mogavero S, Lee S, et al. Nanobody-mediated neutralization of candidalysin prevents epithelial damage and inflammatory responses that drive vulvovaginal candidiasis pathogenesis. mBio. 2024;15(3). doi:10.1128/mbio.03409-23
BibTeX
@article{Valentine2024,
author = {Valentine, Marisa and Rudolph, Paul and Dietschmann, Axel and Tsavou, Antzela and Mogavero, Selene and Lee, Sejeong and Priest, Emily L and Zhurgenbayeva, Gaukhar and Jablonowski, Nadja and Timme, Sandra and Eggeling, Christian and Allert, Stefanie and Dolk, Edward and Naglik, Julian R and Figge, Marc T and Gresnigt, Mark S and Hube, Bernhard},
title = {Nanobody-mediated neutralization of candidalysin prevents epithelial damage and inflammatory responses that drive vulvovaginal candidiasis pathogenesis},
journal = {mBio},
year = {2024},
volume = {15},
number = {3},
doi = {10.1128/mbio.03409-23}
}
EUVIMED